logo-loader
viewGenus plc

Genus confirms sexing semen technology infringed three patents

The litigation forms part of a long-running dispute between ABS Global Inc, Inguran, and Cytonome over the development and launch of Genus' sexed semen technology

Genus plc -

A US court has found that Genus plc’s (LON:GNS) sexing semen technology infringed three patents asserted by Inguran, LLC and Cytonome/ST.

The technology, which competes with ST in the market for processing sexed bovine semen, was being sold by ABS Global Inc under the IntelliGen brand.

A jury at the US District Court for the Western District of Wisconsin ruled that ABS will have to pay a royalty of US$2.60 for each straw of sexed semen produced in the US that were part of the three infringed patents. 

ABS has now modified the IntelliGen technology to avoid continued infringement.

The litigation forms part of a long-running dispute between ABS Global Inc, Inguran, and Cytonome over the development and launch of Genus' sexed semen technology.

In 2014, a court ruled that Inguran and Cytonome wilfully maintained an illegal monopoly in the US market for sexed bovine semen processing. The court found that ABS had infringed a patent and this was sent back for a retrial.

Inguran, and Cytonome filed patent infringement claims against Genus and ABS Global in 2017, claiming ABS’s technology infringed upon seven patents. Ahead of the second trial, ABS successfully demonstrated non-infringement of five of the seven patents and dismissed the trade secret and breach of contract claims. 

"IntelliGen provides farmers and bull studs with a novel technology for sexing bovine semen that focuses on fertility outcomes and has seen a rapid uptake since its launch in 2017,” Genus said.

“ABS will continue to expand and commercialise its IntelliGen technology providing customers and third party bull studs with an alternative service provider, increased competition and improved fertility outcomes.”

Quick facts: Genus plc

Price: 3186 GBX

LSE:GNS
Market: LSE
Market Cap: £2.07 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharma CEO confident as he looks ahead to new Traumakine study

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen caught up with Proactive London's Andrew Scott soon after announcing they've amended the protocol for a second phase III study of its drug for acute respiratory distress syndrome (ARDS). The tweak's in response to...

1 day, 10 hours ago

2 min read